What Researchers Did
Researchers investigated the efficacy of combined mesenchymal stem cell (MSC) transplantation and butylphthalide therapy compared to MSC transplantation alone or hyperbaric oxygen therapy in 42 patients with delayed encephalopathy after carbon monoxide poisoning (DEACMP).
What They Found
At 1, 3, and 6 months post-treatment, patients receiving combined MSC transplantation and butylphthalide showed significantly higher Mini-Mental State Examination and Barthel index scores compared to those receiving MSC transplantation alone or hyperbaric oxygen therapy (all P < 0.0001). No significant adverse events were reported in any treatment group.
What This Means for Canadian Patients
This study suggests that a combination of mesenchymal stem cell transplantation and butylphthalide could be a safe and effective treatment option for Canadian patients suffering from delayed encephalopathy after carbon monoxide poisoning. If confirmed by further research, this therapy could improve cognitive function and daily living activities for those affected.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
A limitation of this study is its relatively small sample size of 42 patients, which may limit the generalizability of the findings.